Humanised anti-CD19 control CAR-T cell therapy - Kite PharmaAlternative Names: Third generation humanised anti-CD19 control CAR-T cell therapy - Kite Pharma
Latest Information Update: 18 Mar 2017
At a glance
- Originator Kite Pharma
- Class Antineoplastics; CAR-T cell therapies
- Mechanism of Action CD19 antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies